Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

Cancer

Volumn 98, Issue 8, 2003, Pages 1643-1648

  Glode, L Michael ^a   Barqawi, Albaha ^a   Crighton, Frances ^b   Crawford, E David ^a   Kerbel, Robert ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Anschutz Cancer Pavilion   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Chemotherapy; Cyclophosphamide; Dexamethasone; Metronomic; Prostate carcinoma

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASTATIN; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRAFT; CAPILLARY RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EDEMA; ENDOTHELIUM CELL; GASTROINTESTINAL SYMPTOM; HORMONE REFRACTORY PROSTATE CARCINOMA; HUMAN; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; METRONOMIC THERAPY; MOON FACE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; VERTIGO;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0141958313     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11713     Document Type: Review

References (34)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Kantoff PW. New agents in the therapy of hormone-refractory patients with prostate cancer. Semin Oncol. 1995;22:32-34.
3. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Huntingt). 1997;11: 180-193.
4. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
5. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2:733-740.
6. Kamen BA, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J Clin Oncol. 2000;18:2935-2937.
7. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
8. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002;8:221-232.
9. Alvarez A, Mickiewicz E, Brosio C, Giglio R, Cinat G, Suarez A. Weekly taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule [abstract 726]. Proc Am Soc Clin Oncol. 1998;17:188a.
10. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-R24.
11. Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 2001;61:7501-7506.
12. Soffer SZ, Moore JT, Kim E, et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg. 2001;36:1177-1181.
13. Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524-532.
14. Machein MR, Kullmer J, Ronicke V, et al. Differential down-regulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol. 1999;25:104-112.
15. Wolff JE, Molenkamp G, Hotfilder M, Laterra J. Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Klin Padiatr. 1997;209:275-277.
16. Saika T, Kusaka N, Tsushima T, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol. 2001;8:290-294.
17. Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89:2570-2576.
18. Morioka M, Kobayashi T, Furukawa Y, et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int. 2002;68:10-15.
19. Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol. 1993;72:625-628.
20. Olson KB, Pienta KJ. Recent advances in chemotherapy for advanced prostate cancer. Curr Urol Rep. 2000;1:48-56.
21. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
22. Asou N, Suzushima H, Nishimura S, et al. Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide. Am J Hematol. 2000;63:35-37.
23. de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001;59:50-56.
24. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV. 15 years follow-up. Ann Oncol. 1994;5:717-724.
25. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73-80.
26. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1198-1203.
27. Kamradt JM, Smith DC, Pienta KJ. Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience. Urol Clin North Am. 1999;26:333-340.
28. Kakolyris S, Samonis G, Koukourakis M, et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol. 1998;21:505-508.
29. Heiss JD, Papavassiliou E, Merrill MJ, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest. 1996;98:1400-1408.
30. Klekamp JG, Jarzecka K, Hoover RL, Summar ML, Redmond N, Perkett EA. Vascular endothelial growth factor is expressed in ovine pulmonary vascular smooth muscle cells in vitro and regulated by hypoxia and dexamethasone. Pediatr Res. 1997;42:744-749.
31. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
32. Derarnaudt TB, da Silva JL, Remy P, Kappas A, Abraham NG. Negative regulation of human heme oxygenase in microvessel endothelial cells by dexamethasone. Proc Soc Exp Biol Med. 1999;222:185-193.
33. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999;5:1107-1113.
34. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res. 1999;5:711-720.